{"id":"NCT03361865","sponsor":"Incyte Corporation","briefTitle":"Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)","officialTitle":"A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-04","primaryCompletion":"2018-08-09","completion":"2020-08-04","firstPosted":"2017-12-05","resultsPosted":"2019-08-29","lastUpdate":"2025-08-22"},"enrollment":93,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["UC (Urothelial Cancer)"],"interventions":[{"type":"DRUG","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"Epacadostat","otherNames":["INCB024360"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pembrolizumab 200 mg + epacadostat 100 mg BID","type":"EXPERIMENTAL"},{"label":"Pembrolizumab 200 mg + placebo BID","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.","primaryOutcome":{"measure":"Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo","timeFrame":"Week 9","effectByArm":[{"arm":"Pembrolizumab 200 mg + Epacadostat 100 mg BID","deltaMin":31.8,"sd":null},{"arm":"Pembrolizumab 200 mg + Placebo BID","deltaMin":24.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":143,"countries":["United States","Australia","Belgium","Canada","France","Germany","Ireland","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["39054491"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":43},"commonTop":["Rash","Anaemia","Asthenia","Diarrhoea","Pruritus"]}}